Clark E Tedford

This inventor holds 18 USPTO granted patents and 27 published patent applications, plus 11 CIPO patents and 11 EPO patents. Top assignees: Omeros Corporation, Lumithera, Inc., University of Leicester. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Clark E Tedford. Retrieved from https://idiyas.com/inventor/clark-e-tedford

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 27)

% Patents Active = 100.0

CIPO Patents = 11 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 21)

Average Co-Inventor Count = 3.5

ph-index = 8

Forward Citations = 195(Granted Patents)

Company Filing History:

University of Leicester

patents

4. 1 out of 14

Rayner Intraocular Lenses Limited

patents

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12390658 - Methods for treating ocular disease (2025-08-19),

2. 12336937 - Multi-wavelength phototherapy devices, systems, and methods for the non-invasive treatment of damaged or diseased tissue (2025-06-24),

3. 12133842 - Stable preservative-free mydriatic and anti-inflammatory solutions for injection (2024-11-05),

4. 11884742 - Methods for treating conditions associated with MASP-2 dependent complement activation (2024-01-30),

5. 11613589 - Compositions for inhibiting MASP-2 dependent complement activation (2023-03-28),

6. 10881550 - Multi-wavelength phototherapy systems and methods for the treatment of damaged or diseased tissue (2021-01-05),

7. 10683367 - Compositions for inhibiting MASP-2 dependent complement activation (2020-06-16),

8. 10596037 - Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatments (2020-03-24),

9. 10219944 - Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatments (2019-03-05),

10. 10047165 - Compositions for inhibiting MASP-2 dependent complement activation (2018-08-14),

11. 9855246 - Stable preservative-free mydriatic and anti-inflammatory solutions for injection (2018-01-02),

12. 9486406 - Stable preservative-free mydriatic and anti-inflammatory solutions for injection (2016-11-08),

13. 9475885 - Compositions for inhibiting MASP-2 dependent complement activation (2016-10-25),

14. 9066856 - Stable preservative-free mydriatic and anti-inflammatory solutions for injection (2015-06-30),

15. 9011860 - Compositions for inhibiting MASP-2 dependent complement activation (2015-04-21),

Title: Clark E. Tedford: Innovator in Ocular Phototherapy

Introduction

Clark E. Tedford is a prominent inventor based in Poulsbo, Washington, known for his significant contributions to the field of ocular disease treatment. With a total of 18 patents to his name, Tedford has focused on developing innovative methods and devices that utilize light therapy to address various eye conditions.

Latest Patents

Tedford's latest patents include groundbreaking methods for treating ocular diseases, particularly dry age-related macular degeneration. These methods involve administering non-invasive photobiomodulation (PBM) light therapy, tailored to the patient's response and pre-treatment characteristics. His work emphasizes the importance of timing, suggesting that PBM therapy can be most effective when administered four to six months after a prior treatment. Additionally, he has developed multi-wavelength phototherapy devices and systems designed to treat damaged or diseased tissue. These devices deliver coordinated doses of light at distinct wavelengths to enhance cellular functionality. Furthermore, his ophthalmic phototherapy devices are specifically designed to promote healing in damaged eye tissue through targeted light exposure.

Career Highlights

Throughout his career, Tedford has worked with notable companies such as Omeros Corporation and Lumithera, Inc. His experience in these organizations has allowed him to refine his expertise in phototherapy and its applications in ophthalmology.

Collaborations

Tedford has collaborated with esteemed colleagues, including James Brian Parent and Thomas Dudler, to advance the field of ocular treatment through innovative research and development.

Conclusion

Clark E. Tedford's contributions to ocular phototherapy represent a significant advancement in the treatment of eye diseases. His innovative methods and devices continue to pave the way for improved patient outcomes in ophthalmology.

Profile summary based on public USPTO records.